Plus Therapeutics to Host Investor Call on Leptomeningeal Cancer Acquisition and FORESEE Trial Data

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing radiotherapeutics for CNS cancers, is set to host an investor call on May 9, 2024, to discuss its recent acquisition of the CNSide cerebrospinal fluid (CSF) testing assets. The call will feature Dr. Marc H. Hedrick, the company's President and CEO, who will provide insights into the rationale behind the CNSide acquisition and offer an overview of the assets obtained. He will also share updates since the September 2023 sublicense of CNSide, including preliminary data from the FORESEE clinical trial and details on future milestones and publications.

The CNSide test is a laboratory-developed test (LDT) based on proprietary technology for capturing and detecting tumor cells in the cerebrospinal fluid. This test aids in identifying molecular treatment targets in patients with metastatic carcinoma or melanoma, providing a unique opportunity to guide therapy selection. The ability to quantitatively measure tumor cells also allows for more effective monitoring of therapy response compared to existing methods.

The FORESEE Study is a multi-center prospective clinical trial that is enrolling patients with either Breast Cancer or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM). Current methods to diagnose or monitor LM, such as clinical evaluation, MRI, and cytology, have limited sensitivity and specificity. The FORESEE trial aims to evaluate how well CNSide monitors LM's response to treatment and its impact on treatment decisions by physicians.

Leptomeningeal Metastases (LM) is a severe cancer complication where the cancer spreads to the cerebrospinal fluid and the leptomeninges surrounding the brain and spinal cord. This condition is more frequently seen in breast cancer, but it can also occur in lung cancer, gastrointestinal cancers, and melanoma. LM affects about 5% of cancer patients and is usually terminal, with very low survival rates beyond one year. The incidence of LM is rising due to longer cancer patient lifespans and the inefficacy of standard chemotherapies to reach therapeutic levels in the spinal fluid.

Rhenium (186Re) obisbemeda is an innovative injectable radiotherapy developed by Plus Therapeutics to deliver high doses of targeted radiation to CNS tumors safely and effectively. This treatment aims to reduce off-target risks and improve outcomes for CNS cancer patients by utilizing the ideal properties of Rhenium-186, including its short half-life and beta energy for tissue destruction. The therapy is currently being evaluated in clinical trials for recurrent glioblastoma and leptomeningeal metastases, with support from the National Cancer Institute (NCI) and a grant from the Cancer Prevention & Research Institute of Texas (CPRIT).

Plus Therapeutics specializes in developing targeted radiotherapeutics for hard-to-treat CNS cancers, aiming to improve patient outcomes through image-guided local beta radiation and targeted drug delivery. The company has built a comprehensive supply chain and established strategic partnerships to support the development, manufacturing, and potential commercialization of its products. Plus Therapeutics operates in key cancer clinical development hubs in Austin and San Antonio, Texas, and is led by a skilled leadership team dedicated to advancing their therapeutic pipeline.